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SUMMARY 
 
The development of an effective vaccine against human immunodeficiency virus 
(HIV) is considered to be the most practicable means of controlling the advancing 
global AIDS epidemic.  Studies in the domestic cat have demonstrated that vaccinal 
immunity to infection can be induced against feline immunodeficiency virus (FIV), 
however, protection is largely restricted to laboratory strains of FIV and does not 
extend to primary strains of the virus.  We compared the pathogenicity of two 
prototypic vaccine challenge strains of FIV derived from molecular clones; the 
laboratory strain PETF14 and the primary strain GL8414.  PETF14 established a low viral 
load and had no effect on CD4+ or CD8+ lymphocyte subsets. In contrast, GL8414 
established a high viral load and induced a significant reduction in ratio of CD4+ to 
CD8+ lymphocytes by 15 weeks post infection, suggesting that PETF14 may be a low 
virulence challenge virus. However, during long-term monitoring of the PETF14-
infected cats, we observed the emergence of variant viruses in two of three cats. 
Concomitant with the appearance of the variant viruses, designated 627W135 and 
628W135, we observed an expansion of CD8+ lymphocyte subpopulations expressing 
reduced CD8β-chain, a phenotype consistent with activation.  The variant viruses 
both carried mutations that reduced the net charge of the V3 loop (K409Q and 
K409E), giving rise to a reduced ability of the Env proteins to both induce fusion and 
to establish productive infection in CXCR4-expressing cells.  Further, following 
subsequent challenge of  naïve cats with the mutant viruses, the viruses established 
higher viral loads and induced more marked alterations in CD8+ lymphocyte 
subpopulations than the parent F14 strain of virus, suggesting that the E409K 
mutation in the PETF14 strain contributes to the attenuation of the virus. 
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INTRODUCTION 
 
Infection of the domestic cat with feline immunodeficiency virus (FIV) leads to the 
development of an immunodeficiency syndrome similar to AIDS in  human beings 
infected with human immunodeficiency virus (HIV). FIV-infected cats are more 
likely to develop illnesses including gingivitis, stomatitis, lymphoma, neurological 
disorders and wasting (15;24). Flow cytometric analyses have demonstrated a 
reduction in the number of circulating CD4+ lymphocytes in FIV-infected cats (1;22) 
and longitudinal studies have revealed that the degree of immune impairment 
correlates with the decline in CD4+ lymphocyte numbers (34), suggesting that, as 
with HIV infection in man, the primary lesion in the FIV infected cat is an impairment 
of helper T-cell function.  During the early, acute phase of infection, the inversion of 
the CD4:CD8 ratio is compounded by a sharp increase in CD8+ T-lymphocytes 
expressing low levels of CD8 (CD8low) and increased levels of major 
histocompatibility (MHC) class II antigens (39). This activated T-cell subpopulation 
persists throughout the course of the infection, suggesting that the early interaction 
between the virus and the immune system may ultimately determine the outcome of 
the infection.  CD8low cells have since been defined as CD8α+βlow (28;29); the vpg9 
antibody used in previous studies being shown to recognise the CD8αβ heterodimer. 
An analogous population has since been described in HIV-infected individuals in 
whom reduced expression of the CD8αβ heterodimer correlates with increased 
expression of molecules associated with lymphocyte activation, adhesion and 
cytotoxic T cell activity (27).   Further, a significant increase in expression of the 
CD8αβ heterodimer followed initiation of highly active antiretroviral therapy 
(HAART) suggesting that analysis of discrete CD8+ T lymphocyte subsets may be of 
value in assessing the immune status of individuals infected with HIV-1 (27). 
Previously, we demonstrated that vaccination with whole-inactivated virus 
vaccines or DNA vaccines  afforded protection against challenge with the cell culture-
adapted PET strain of FIV but not against the primary GL8 strain (10;12;13).  The 
induction of protective immunity against primary strains of FIV such as GL8 has 
proved difficult; outcomes ranged from a suppression of the PBMC viral load and 
CD4+ T cell loss with a whole inactivated virus vaccine (12), to enhancement of 
infection following immunisation with FIV p24-ISCOMS (14).  Encouragingly, 
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protective immunity has been induced following immunisation with a fixed, infected 
cell vaccine based on the MBM cell line (19) and, in field studies, this vaccine 
provided immunity to infection following natural exposure to the virus (20).   The 
success of the fixed cell vaccine may be associated with the observation that the 
vaccine was based on cells infected with a clade B virus strain (Pisa M2), and the 
vaccine was tested in a region in which clade B viruses are almost exclusively found 
(20;25). Previous studies have suggested that clade B viruses such as Pisa M2 may be 
more ancient and relatively host-adapted while clade A viruses may have entered their 
host population more recently and thus may be more virulent (2;25). As clade A 
viruses are widespread in the USA and Northern Europe, it is important to establish 
the determinants of virulence in these viruses. 
 Cell culture-adapted strains of FIV such as PET differ from primary strains of 
FIV in that they have an expanded cell tropism that permits growth in established cell 
lines such as Crandell feline kidney cells (CrFK) or 3201 cells. The underlying 
mechanism for the expanded cell tropism involves an increase in charge of the V3 
loop of the viral envelope glycoprotein (Env) gp120 (31;36). This increase in charge 
of the V3 loop facilitates the usage feline CXCR4 as a sole receptor for infection 
(11;37;41;42), possibly in conjunction with heparan sulphate (5) and analogous to 
CD4-independent infection with HIV-2 (8).  In contrast, while infection with most 
primary strains of FIV is CXCR4-dependent (7;26), the existence of an, as yet, 
unidentified high affinity non-CD4 primary receptor has been suggested (5;38). 
In this study, we compared the virulence of two prototypic clade A vaccine 
challenge strains of  FIV derived from stable molecular clones, PETF14 and GL8414.  
We demonstrate that the GL8414 molecular clone has similar virulence characteristics 
to the biological isolate of the virus from which it was derived, establishing a high 
viral load and inducing marked alterations in circulating CD4+ and CD8+ lymphocyte 
sub-populations. In contrast, the PETF14 virus established a low viral load and had 
little effect on the CD4+ and CD8+ lymphocyte sub-populations.  Further, we show 
that the emergence of more virulent strains of PETF14 in vivo is associated with 
alterations in the way the virus uses CXCR4 as a  receptor for infection. 
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MATERIALS AND METHODS 
 
Viruses and cell lines.  All cell culture media and supplements were obtained from 
Invitrogen Life Technologies Ltd., Paisley, UK. Adherent cell lines were maintained 
in Dulbecco’s modification of minimum essential medium (DMEM) supplemented 
with 10% foetal bovine serum (FBS), 2mM glutamine,  0.11mg/ml sodium pyruvate, 
100 IU/ml penicillin and 100 μg/ml streptomycin (DMEM).  The IL2-dependent 
feline T cell line Mya-1 (21) and peripheral blood mononuclear cells were maintained 
in RPMI1640 medium supplemented with 10% FBS, 2mM glutamine, 100 IU/ml 
penicillin,100 μg/ml streptomycin, 5 x 10-5 M 2-mercaptoethanol and 100IU/ml 
recombinant human interleukin 2  (RPMI).  
The challenge viruses were prepared from the GL8414 (12) and PETF14 (33) 
molecular clones of  FIV.  Molecular clones were transfected in the murine fibroblast 
cell line 3T3 using Superfect transfection reagent (QIAgen, Valencia,CA.). 72 hours 
post transfection, supernatants were harvested, 0.45μm filtered and used to infect the 
IL2-dependent feline T cell line Q201 (40).  The infected cultures were monitored 
visually for cytopathicity and for the production of FIV p24 by enzyme-linked 
immunosorbent assay (ELISA, PetCheck FIV antigen ELISA, IDEXX Corp., 
Portland, Maine, USA). Supernatants were collected at peak cytopathicity/ p24 
production, 0.45μm filtered, dispensed into 1ml aliquots and stored at –70oC. 
 
Quantification of proviral load in peripheral blood mononuclear cells.  The FIV 
proviral load in PBMC was quantified using real-time PCR measuring PCR product 
accumulation through a dual-labeled fluorogenic TaqMan probe (9).  The primers 
used were FIV0771f (5’-AGA ACC TGG TGA TAT ACC AGA GAC-3’) and 
FIV1081r (5’-TTG GGT CAA GTG CTA CAT ATT G-3’).  The probe used in this 
system was FIV1010p (5’-FAM-TAT GCC TGT GGA GGG CCT TCC T-TAMRA-
3’).  The oligonucleotides were designed to detect a variety of FIV A-subtype isolates 
and have been previously shown to detect FIV-PET, FIV-GL8 and FIV-AM6 with 
only minor differences in the PCR efficiency (17,18).  The 25 µl PCR mixtures 
contained 10 mM Tris (pH 8.3), 50 mM KCl, 3 mM MgCl2, 200 nM dATP, dCTP, 
dGTP, 400 nM dUTP, 300 nM of each primer, 200 nM of the fluorogenic probe and 
2.5 units of Taq DNA polymerase.  After the initial denaturation (2 min. at 95oC), 
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amplification was performed with 45 cycles of 15 sec at 95oC and 60 sec at 60oC.  
The PCR reaction and the on-line measurement of the emitted fluorescence were 
performed on a Sequence Detector System ABI 7700 (Applied Biosystems, Foster 
City, California).  The copy number per PCR reaction was calculated by the Sequence 
Detection Software version 1.6.3 (Applied Biosystems, Foster City, California) 
utilizing a fourfold dilution series of genomic DNA derived from a CrFK cell line 
infected with FIV Petaluma. The DNA content per PCR reaction was estimated by a 
second real-time PCR assay targeting the 18 S rDNA genes (16).   
 
Quantification of viral load in plasma.  The FIV viral load in plasma was quantified 
by real-time RT-PCR using the same primers as in the real-time PCR. The 25 µl RT-
PCR reaction mixtures contained 12.5 µl 2x Thermoscript Reaction Mix (Platinum 
Quantitative RT-PCR Kit, Life Technologies, Karlsruhe, Germany), 300nM of each 
primer, 200 nM of the fluorogenic probe, 0.5 µl of the Thermoscript Plus/Platinum 
Taq Enzyme mix, 20 U of RNaseOUT (Life Technologies, Karlsruhe, Germany) and 
5 µl of the sample. After a reverse transcription step of 30 min. at 60oC followed by a 
denaturation step (5 min. at 95oC), amplification was performed with 45 cycles of 15 
sec at 95oC and 60 sec at 60oC. 
 
Virus isolation. Virus isolation from PBMC by bulk cell culture was performed as 
described previously (12).  PBMC were fractionated from 5ml  of whole blood by 
centrifugation over Ficoll Paque density 1.077g/ml. The separated PBMC were co-
cultured with Mya-1 cells in the absence of mitogenic stimulation. We have found 
that this protocol enables the isolation of both primary and cell culture-adapted strains 
of FIV and does not exert a selective pressure on the virus that is isolated e.g. Mya-1 
cells will support the growth of PETF14 and GL8414 equally and the viruses harvested 
from the cells retain their specific cell tropisms. 
 
Antibodies and flow cytometry. Antibodies were used either un-conjugated or as 
phycoerythrin (PE) or fluorescein isothiocyanate (FITC) conjugates. Anti-feline CD4-
FITC (vpg34) and CD8αβ-PE (vpg9) were obtained from Serotec Ltd., Oxford, U.K; 
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anti-feline CD8α (12A3) from Y. Nishimura, University of Tokyo, Tokyo, Japan; 
anti-feline CD8β-FITC and PE (FT2) from Southern Biotechnology Ltd., U.S.A. 
FITC-conjugated anti-feline CD8α (12A3) was prepared using FITC-coupling reagent 
(Pierce Chemical Co., Rockford, IL) according to the manufacturers instructions. Un-
conjugated primary antibodies were detected using FITC or PE-coupled F(ab’)2 
fragment of sheep anti-mouse IgG whole molecule (Sigma). EDTA anti-coagulated 
blood was processed for flow cytometric analyses by whole blood lysis as described 
previously (39).  Samples were analysed on  a Beckman Coulter Epics Elite flow 
cytometer and 10,000 events were collected for each sample. Data were analysed 
using Expo32 ADC software (Applied Cytometry Systems, Sheffield, U.K.). 
 
Molecular cloning and nucleic acid sequencing.  DNAs were prepared from 
positive viral isolations by column chromatography (QIAamp DNA maxiprep kit, 
Qiagen).  DNAs were prepared as soon as a positive ELISA test for FIV p24 was 
recorded, thus viruses had undergone minimal passage in vitro. Full length viral 
envelope glycoprotein (env) genes were amplified from the replication competent 
viruses by using a high fidelity (proof reading) polymerase chain reaction (High 
Fidelity PCR system, Roche) using primers corresponding to the 5’ L-SU cleavage 
site (TAGACGCGTAAGATTTTTAAGGTATTC) and the NdeI site 3’ of the RRE 
(CCCTTTGAGGAAGATGTGTCATATGAATCCATT) incorporating MluI and 
NdeI restriction sites respectively .  Due to the inherent instability of the full-length 
env genes from primary isolates of FIV such as GL8, standard high copy number PCR 
product cloning vectors could not be used, thus all amplified env gene products were 
digested with MluI/NdeI and cloned directly into pGL8MYA, a molecular clone of FIV-
GL8 in the low copy number plasmid pBR328 and in which an MluI site has been 
introduced at the L-SU junction.  The nucleic acid sequence of three independent 
clones of each env gene were detemined using IRD800 labelled oligonucleotides on 
an automated sequencer (LI-COR Biosciences, Lincoln, Nebraska, USA).  
 
In vitro expression of env genes. The biological function of each env gene clone was 
confirmed by the recovery of infectious virus following transfection and by  
immunofluorescence detection of the Env glycoprotein with an anti-FIV Env 
monoclonal antibody (vpg71.2).  For the recovery of infectious virus, 293T cells were 
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transfected using Superfect (QIAgen) as per manufacturers instructions.  Supernatants 
were collected 48-72hrs post transfection, filtered at 0.45μm and added to Mya-1 
cells.  The infected cells were monitored for the production of FIV using the 
PetCheck FIV antigen ELISA (IDEXX Corp., Portland, Maine, USA).   
Immunofluorescence was performed on transfected 293T cells following 
fixation with ice-cold methanol.  Fixed cells were re-hydrated using phosphate 
buffered saline containing 1.0% bovine serum albumin and 0.1% azide (PBA). The 
cells were then incubated with either 1μg of vpg71.2 or an isotype-matched control 
for 30 minutes on ice, washed twice with PBA by centrifugation, and then incubated 
with FITC-coupled F(ab’)2 fragment of sheep anti-mouse IgG whole molecule on ice 
for a further 30 minutes. Finally, the cells were washed twice with PBA and then 
analysed on a Leica UV microscope. 
To assess the fusogenicity of the FIV Env proteins, the env genes were sub-
cloned into the mammalian expression vector VR1012 (Vical Incorporated, San 
Diego, CA.). AH927 cells expressing feline CXCR4 were transfected with the 
constructs using Superfect (Qiagen) and incubated for 48 hours at 37oC.  The cells 
were then fixed and stained with 1% methylene blue/ 0.2% basic fuchsin in methanol. 
Syncytia were enumerated by light microscopy using a x12.5 Leitz periplan eyepiece 
with a 6.5x9 graticule, three separate fields being counted per well, each well in 
duplicate.  Syncytia were scored as cells with five or more nuclei. 
The growth of FIV in vitro was assessed in AH927 cells expressing feline 
CXCR4. AH927 cells were transduced with retroviral vectors (pDONAI, Takara 
Biotech., Japan) expressing feline CXCR4 or CCR5 and selected in G418.  Stable 
transfectants were seeded in 48-well cell culture plates and were then infected with 
two-fold dilutions of virus grown in IL2-dependent T cells.  Supernatants were 
collected every three days and assayed for the production of reverse transcriptase 
(RT) using Lenti-RT non-isotopic RT assay kit (Cavidi Tech., Uppsala, Sweden). RT 
values were then calculated relative to purified HIV-1 RT standard. 
 
 
 
 
 9
RESULTS 
 
Early infection 
FIV GL8 rapidly establishes a high viral load.   Three groups of three cats were 
infected with either a matched dose of FIV GL8414 or PETF14, or were mock-infected. 
Samples of peripheral blood were collected at regular intervals after infection and the 
PBMC proviral DNA burden was quantified by real-time PCR (Fig. 1a). The proviral 
loads in the GL8414-infected cats rose sharply with approximately 1.0% of PBMC 
being positive for proviral DNA by 6 weeks post infection.  This high proviral burden 
was maintained throughout the acute phase of infection, and during the first 35 weeks 
of the study period.  In contrast, the PETF14 inoculum established a significantly lower 
proviral load, with a load of approximately 0.01% being achieved during the acute 
phase (Fig 1a). During this period, the effect of viral infection on the CD4:CD8 ratio 
was monitored by flow cytometry.  Coincident with the sharp rise in proviral load in 
the GL8414 infected cats was a marked decline in the CD4:CD8 ratio manifesting by 
six weeks post infection (Fig1b). In contrast, the CD4:CD8 ratios of the PETF14 
infected cats did not differ significantly from the controls.  
 
Expansion of CD8α+/βlow  T  lymphocytes in GL8414-infected cats.  Previously, we 
demonstrated that the biological isolate of GL8 induced rapid alterations in the CD8+ 
lymphocyte subset characterised by reduced expression of CD8 (CD8low) (39).  
Subsequently, the CD8low population was revealed to consist of CD8αβlow and 
CD8αα’ populations (28;29), analogous to the population described in HIV-infected 
individuals (27). The absolute numbers of CD4+, CD8+ and CD8αβlow were 
determined in the three groups of cats (Fig.2).  CD4+ lymphocyte numbers  dropped 
sharply in both the GL8414 and PETF14–infected cats at 3 weeks post infection.  
However this proved to be a transient fall as the levels rebounded by 6 weeks post 
infection. Although the data suggest that there was a downward trend in the CD4+ 
lymphocyte numbers in both the FIV-infected groups it was not until 67 weeks post 
infection that the reduction in the CD4+ lymphocyte number in the GL8414-infected 
cats reached statistical significance (P=0.046, t-test).  The major contributing factor to 
the depressed CD4:CD8 ratio in the GL8414-infected cats was a transient, sharp 
increase in the number of CD8+ lymphocytes (Fig. 2b). When the analysis gates  for 
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flow cytometry are focussed on the CD8αβlow subset (Fig. 2c), it can be seen that this 
population expands by 9 weeks post infection to a maximum of 1.0x109/l, returning to  
pre-infection levels (<0.4x109/l) by 32 weeks post infection.  Due to the small 
numbers of cats in each group the elevated numbers of CD8αβlow  lymphocytes did 
not reach statistical significance. In contrast to the GL8414-infected cats, CD8αβlow  
lymphocytes could not be detected at any of the time points during the acute phase of 
infection in the PETF14-infected cats.  The data indicate that the virus derived from the 
GL8414 molecular clone is as pathogenic as the original biological isolate of GL8 and 
that cats infected with the GL8414 or PETF14 viruses can be differentiated readily on 
the basis of viral load. Further, at no point during the early acute phase of infection 
did we observe the CD8αβlow subset  in PETF14-infected cats, consistent with the this 
subset being a marker for infection with a more pathogenic strain of FIV, such as 
GL8414.  
 
Long-term infection 
Emergence of pathogenic variants of FIVF14 during prolonged infection.  
Throughout the acute phase of infection, virus could be isolated readily in vitro from 
PBMC cultures from both groups of infected cats (data not shown). By 32 weeks post 
infection, virus isolation became sporadic from the PETF14-infected cats, consistent 
with the low viral loads indicated by real-time PCR (Fig. 1).  In contrast, virus could 
be isolated readily  from GL8414-infected cats at all time points (data not shown). 
These findings may indicate that the immune response to infection was limiting the 
replication of PETF14, but not of GL8414 and are consistent with the contention that the 
PETF14 virus is less virulent than GL8414.   Following the early peak in viral load 
during the acute phase of infection, the proviral burden in the PBMC of the PETF14-
infected cats fell below the level of assay sensitivity.  In contrast, a high proviral 
burden was maintained in the GL8414-infected cats throughout the study period 
(Figure 3). 
 By 144 weeks post infection bulk virus isolations from PBMCs from cats 627 
and 628 tested positive, despite the PBMC proviral load remaining below assay 
sensitivity (<1x10-5 % infected PBMC) . Coincident with the positive virus isolations, 
we observed the expansion of the CD8αβlow subset in the same cats (Figure 4). As we 
had not observed an expansion of  CD8αβlow subset in the PETF14-infected cats at any 
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time point during the acute phase of infection, we postulated that virulent escape 
mutants may have evolved with time post infection.   
 
Characterisation of the emergent virus strains from PETF14-infected cats. Virus 
was isolated from peripheral blood mononuclear cells from cats A627 and A628 and 
the env genes amplified by high-fidelity PCR and cloned. The nucleic acid sequence 
of the env clones was then determined and the predicted amino acid sequence 
translation established. Fig.5 illustrates the predicted amino acid sequence of the Env 
region from V3 through to V6, a region that has been shown previously to contain 
determinants of cell tropism (31;36) and CXCR4 usage (5;42).  The mutation of either 
of two glutamate residues in V3 (residues 407 and 409 in GL8414 in Fig. 5) to lysine 
residues is thought to determine the usage of CXCR4 as a sole receptor (analogous to 
CD4-independent infection with HIV). The PETF14 virus contains a lysine residue at 
position 409.  In the virus re-isolated from cats 628 at 135 weeks post infection 
(628W135), lysine 409 had been replaced with a glutamate residue (K409E), analogous 
to GL8414 which reduces the net charge of the V3 loop by replacing a positively 
charged residue with a negatively charged residue.  A second coding mutation 
(S557N) observed in the re-isolate from cat 628 introduced a predicted N-linked 
glycosylation site in the V5 region.  Intriguingly, the week 135 re-isolate from cat 627 
(627W135) also showed a mutation at position 409 in the V3 loop (K409Q), replacing a 
positively charged residue with a neutral residue, again reducing the net charge of the 
V3 loop.  A second mutation (N422T) removed a predicted site for N-linked 
glycosylation from the region at the base of the V3 loop.  Given that the glutamate 
residues 407 and 409 are known to be critical determinants of the interaction between 
FIV and CXCR4, the data suggest that there may be a direct link between CXCR4-
usage and virulence.   
 Given that changes in the TM protein of FIV affect cell tropism (35), we 
compared the sequences of the TM protein of the 627W135 and 628W135 clones with the 
parent PETF14.  The TM sequence of 628W135 Env showed no changes from the 
parental virus while the TM sequence of 627W135 showed two coding mutations 
distinct from those described previously to affect cell tropism.  As these changes were 
not common to the 627W135 and 628W135 viruses they are unlikely to be responsible for 
the reversion to a virulent phenotype. Similarly, of the changes observed in the region 
of SU between the L-SU cleavage site and V3, only a conservative change F208L, 
 12
was observed in both 627W135 and 628W135. 628W135 displayed additional T154K 
(neutral hydrophilic to basic) and R252G (basic to amphiphilic) changes, while an 
additional F388L (conservative) substitution was detected in 627W135.   
 
In vitro properties of the reverted viruses.  E407K and E409K substitutions in the 
V3 loop of FIV SU alone are sufficient to permit infection of CrFK cells with FIV and 
CrFK-tropic viruses bind CXCR4 with a high affinity (31).  Data presented to date 
suggest that infection of adherent cell lines such as CrFK cells requires an interaction 
between the viral envelope glycoprotein and CXCR4 (5;11;42) and heparan sulphate 
(5), indeed ectopic expression of CXCR4 is sufficient to render cells permissive for 
syncytia formation and cell-free virus infection with CrFK-adapted strains of FIV 
(viruses carrying E to K mutations in the V3 loop) (36;37;42).  In contrast, ectopic 
expression of feline CXCR4 or CCR5 does not render cells permissive to infection 
with primary strains of FIV such as GL8, leading to the proposal  the primary strains 
utilise an as yet unidentified high affinity binding receptor for infection of primary 
IL2-dependent T cells (37). Recent compelling evidence revealed that recombinant 
FIV envelope glycoproteins bind distinct cell surface molecules on lymphoid cell 
lines compared with adherent cell lines, further implicating a high affinity primary 
binding receptor for attachment to these cell lines (5).  The PETF14 virus represents a 
CrFK-adapted strain of FIV, the viral envelope glycoprotein binds to CXCR4 with a 
high affinity and expression of the envelope glycoprotein alone in CXCR4-expressing 
cells promotes syncytium-formation (11;37).  We therefore assessed the in vitro 
properties of the PETF14 revertant viruses 627W135 and 628W135 in comparison with the 
parental PETF14 virus, the GL8414 virus, and a mutant GL8 envelope glycoprotein 
bearing an E407K mutation (GL8E407K). DNAs encoding the envelope glycoproteins 
were sub-cloned into a mammalian expression vector (VR1012) and transfected 
directly into the feline cell line AH927 stably expressing feline CXCR4 (Fig.6) or 
CCR5 (not shown).  Marked syncytium formation was observed in the cultures 
transfected with the PETF14 env construct (Fig. 6a.), the syncytia often being large 
(>20 nuclei per syncytium, 30+/-2 per field).  In contrast, the number of syncytia in 
the GL8414-transfected cultures (0.2+/-0.2 per field) did not differ from the cultures 
transfected with the vector alone (0.2 +/- 0.2 per field).  The 627W135 and 628W135  env  
genes gave an intermediate phenotype,  with fewer, smaller syncytia (5-10 nuclei per 
syncytium, 2.4+/-1.5 per field and 4.4+/-2.3 per field respectively). The GL8E407K 
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mutant gave a similar size and number  of syncytia to the 627W135 and 628W135.  No 
syncytia were observed  in AH927 cells stably expressing feline CCR5 following 
transfection with the envelope constructs (not shown). The data suggest that the 
observed reduction in net charge of the V3 loop of 627W135 and 628W135 resulted in an 
impaired  ability to induce syncytia in CXCR4-expressing feline cells compared with 
the parental PETF14 strain.  Further, despite having a significantly reduced ability to 
induce syncytia formation in CXCR4-expressing cells, the retention of a degree of 
syncytium-forming capacity by the 627W135 and 628W135  envelope glycoproteins 
suggest that other regions in the parental PETF14 envelope glycoprotein contribute to 
its highly fusogenic phenotype.  Accordingly, while the E407K mutation rendered the 
GL8 envelope glycoprotein fusogenic, the extent of syncytium formation was 
markedly lower than that of the PETF14 envelope glycoprotein.  
The ability to form syncytia in adherent cell lines appears to be dependent on 
the expression of CXCR4 (41;42) and the binding of recombinant envelope 
glycoprotein involves an interaction with both CXCR4 and heparan sulphate (5). 
Therefore we asked whether the reduction in the net charge of the V3 loop of the 
627W135 and 628W135 viruses affected the growth of the viruses in vitro in established 
cell lines.  The PETF14, GL8414, 627W135 and 628W135 viruses were used to infect 
AH927 cells stably expressing feline CXCR4, since these cells are known to support 
the growth of viruses carrying an Env protein adapted for growth in cell culture (the 
use of CXCR4 as a sole receptor), while restricting the growth of viruses carrying 
primary Env proteins (our unpublished observations). In agreement with the studies 
on the fusogenicity of the viral Env proteins,  AH927-FX4 cells supported the growth 
of PETF14 but not GL8414.  Growth of the 627W135 and 628W135 viruses was severely 
impaired but was detectable (Fig. 7).  Furthermore, the CXCR4 antagonist AMD3100 
inhibited the growth of the PETF14, 627W135 and 628W135 viruses (Fig. 7), thus 
confirming that while infection was less efficient, it was CXCR4-dependent.  
Infection of AH927-FX4E with the PETF14, 627W135 and 628W135 viruses was sensitive 
to pre-treatment of the cells with heparinase (data not shown), suggesting that heparan 
sulphate may play a role in infection of this cell line with these viruses.  These 
findings are in accord with previous findings in which heparan sulphate was found to 
be required for binding of recombinant 34TF10 FIV SU to adherent cell lines. As all 
four viruses grew readily in IL2-dependent T cells (data not shown), the data confirm 
that the mutations detected in the V3 loop of the 627W135 and 628W135 viruses lead to a 
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partial restoration of the characteristics of a primary isolate (loss of the ability to 
replicate in CXCR4-expressing adherent cell lines).  However, the reduced 
fusogenicity (Fig. 6) and  growth (Fig. 7) of the 627W135 and 628W135 viruses suggests 
that the viruses harbour determinants outwith the V3-V6 region of Env that are 
required for efficient replication in these cells. 
 
Virulence of the 627W135 and 628W135 viruses in vivo 
 
The data presented above suggest that the 627W135 and the 628W135 viruses have 
reverted to a more pathogenic phenotype than the parental PETF14 molecular clone. In 
order to test this hypothesis, we infected three groups of cats with matched doses of 
either the PETF14, 627W135 or  628W135 viruses.  Our previous data had indicated that 
the major differences between the GL8414 and PETF14 viruses were 1) viral load and 2) 
expansion of CD8+ lymphocyte subpopulations.  GL8414 achieved a high viral load 
and triggered an expansion of CD8+ lymphocytes expressing reduced CD8β 
(CD8βlow) while PETF14 achieved a lower viral load and did not affect CD8+ 
lymphocyte subpopulations. Following infection with the 628W135 virus, marked 
increases in both proviral load (Fig. 8a) and plasma viral load (Fig. 8b) were detected 
as early as 3 weeks post-infection.  These increased proviral and viral loads were 
mirrored by an expansion of lymphocytes expressing CD8βlow (Fig. 8c). In contrast, 
while infection with the 627W135 virus achieved a similar initial plasma viraemia at 3 
weeks post infection, by week 6 the levels of virus in plasma had dropped markedly. 
Flow cytometric analysis of peripheral blood lymphocytes from these cats revealed a 
transient increase in lymphocytes expressing CD8βlow at 7 weeks post-infection 
returning to control levels by 12 weeks post-infection. Infection with PETF14 resulted 
in a transient plasma viraemia at 3 weeks post-infection, returning to baseline levels 
by 7 weeks post-infection. While a small increase in lymphocytes expressing 
CD8βlow was observed in the PETF14 infected cats at 7 weeks post-infection, the 
increase was markedly reduced compared to the cats infected with 627W135, and in 
particular 628W135. Thus infection of naïve cats with the 627W135 and 628W135 viruses 
reproduced the alterations observed in the immune systems of cats A627 and A628 
with the emergence of the mutant viruses. Further, the infection experiments suggest a 
correlation between viral load and the expansion of lymphocytes expressing 
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CD8βlow. The data  confirm that the 627W135 and 628W135 viruses are more 
pathogenic than the parental PETF14 virus. 
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DISCUSSION 
 
In this study we compared the pathogenicity of two strains of FIV used routinely as 
challenge strains for vaccine studies.  As the viruses were derived from molecular 
clones, they represent a reproducible source of virus for inter-study comparison. 
While it is possible to induce protective immunity to infection with the PET isolate 
(10;43), the GL8414 strain represents a more stringent challenge. To date, protective 
immunity has not been observed against the GL8 isolate of FIV, although a reduction 
in viral load has been observed following immunisation with a whole inactivated virus 
vaccine (12).  The data presented here suggest that the GL8 strain of FIV is 
intrinsically more pathogenic than the PET strain of  FIV, a strain of virus that has 
been suggested to be of low pathogenicity (6;12).  Using minimally-passaged virus 
derived from the GL8414 molecular clone of FIV, we have established that GL8 
achieves a significantly greater viral load in infected cats than PET (approximately 
100-fold higher).  Further, the GL8414-derived virus reproduces the sharp drop in the 
CD4:CD8 ratio described previously for the biological isolate of GL8 (39) and 
representative of pathogenic strains of FIV(1;22;44).  Having established that the 
PETF14-derived virus was less virulent than the GL8414-derived virus, we followed the 
two groups of infected cats and noted the emergence of pathogenic variants of PETF14 
in two of the infected cats 135 weeks after infection (627W135 and 628 W135).  The Env 
sequences of these viruses displayed characteristic changes in the V3 loop residues 
that are known to govern the ability of FIV to infect CXCR4-expressing adherent cell 
lines.  Subsequently, we showed that the mutant viruses had a greatly reduced ability 
to trigger syncytium formation, were less able to establish a productive infection in 
adherent cells expressing CXCR4 and were more pathogenic than the parental PETF14 
virus when inoculated in vivo. 
 The reversion from an avirulent (PETF14) to a virulent phenotype (627W135 and 
628 W135) at approximately two years post infection is of particular significance given 
that “attenuated” laboratory strains of FIV have been suggested as potential vaccines 
for protection against virulent strains of the virus. Many laboratory strains of FIV 
display an increase in the net charge of the V3 loop (e.g. PETF14(23), PET34TF10 (33), 
UT113 (36), AM6 (31) and GL8CrFK (37)) analogous to CD4-independent strains of 
HIV.  The increase in charge of the V3 loop correlates with enhanced replication in 
CXCR4-expressing feline cell lines such as CrFK (31;36).   It is thought that such 
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mutations enable the virus to infect cells in the absence of an as yet unidentified 
primary receptor (37;38), perhaps by facilitating a direct interaction with CXCR4.  
Alternatively, it is possible that the decreased net charge of the V3 loop in A627W135 
and A628W135 might result in either a decreased ability of these viruses to adsorb 
efficiently to the cell surface via heparan sulphate (5).  Indeed, it is conceivable that 
the limited replication of PETF14 in vivo may result from the virus being trapped on 
endothelial cells and other tissues expressing large amounts of heparan sulphate on 
their surface. 
Using the PETF14 as a typical CXCR4-tropic strain of FIV, we show here that 
while this phenotype is positively selected in vitro, it is not stable in vivo.  Further, 
given that PETF14 neither established a high viral load nor induced the expansion of 
activated CD8+ T lymphocyte sub-populations, and the emergence of the variants 
627W135 and 628W135 coincided with the expansion of  CD8+ lymphocyte populations 
and an increased frequency of successful virus isolations, the data suggest that the V3 
loop mutation associated with high affinity CXCR4 usage in vitro leads to attenuation 
in vivo.   
The sequence changes that were detected in the V3 loop of the envelope 
glycoprotein may have arisen as a result of selection from virus neutralizing 
antibodies, since this region represents a major neutralizing determinant for FIV.  It is 
possible that the PETF14 is more readily neutralizable than the 627W135 and 628W135 
variants, thus accounting for the lower viral load in PETF14 infected cats.  In previous 
studies, escape from neutralizing antibodies was correlated with mutations in the V4 
or V5  regions of the virus, the emergence of neutralization resistant strains having 
been examined both in vitro and in vivo (3;4;30;32). By comparison, however, we did 
not observe consistent changes in this region of the 627W135 and 628W135 variants.  
Neither re-isolate contained mutations in the V4 region  and while 628W135 had 
acquired a mutation that would give rise to a predicted N-linked glycosylation site 
(S557N), this was not present in the 627W135 re-isolate.  While the additional 
glycosylation site in V5 of 628W135 may confer a replicative advantage to the virus by 
conferring resistance to neutralising antibodies, this alone was clearly not the main 
determinant of virulence.  In contrast, the K409Q and K409E mutations in the 627W135 
and 628W135 variants are consistent with previous in vivo selected variants based on 
the PET34TF10 clone of FIV (3;4). The PET34TF10 clone of FIV has lysine residues at 
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positions 407 and 409 in the V3 loop.  However following passage in vivo, the re-
isolated virus showed K407E and K409G mutations (4).    
 The emergence of the 627W135 and 628W135 variants in the PETF14–infected cats 
correlated well with the appearance of activated CD8+ lymphocyte subpopulations, 
characterised by reduced expression of CD8β.  One of the first indications that more 
virulent viruses had evolved in cats 627 and 628 was an increased frequency with 
which virus could be isolated from bulk PBMC cultures.  As real-time PCR for 
proviral DNA load in PBMC during this period remained consistently negative, the 
data suggest that although the viral load had increased in the cats, the levels of virus 
were still very low, below the assay sensitivity of 1x10-5% infected PBMC. In 
contrast, the proviral loads in the GL8414-infected cats remained high throughout the 
study.  If the variant viruses in cats 627 and 628 were more virulent than the parental 
PETF14 virus, we would have expected an increased proviral load following the 
emergence of the variant viruses. The finding that the proviral load remained below 
the sensitivity of the real-time PCR assay may indicate suppression of viral replication 
by the host immune response. We addressed this possibility by challenging three 
groups of naïve cats with either the variants 627W135 and 628W135, or the parental virus 
PETF14. Following challenge, the variant viruses achieved higher viral loads than the 
parental strain, indicating that in the absence of a pre-existing immune response the 
viruses were more virulent than the parental strain. Further, infection with the 627W135 
and 628W135 viruses induced a concomitant expansion of CD8βlow lymphocytes.  
 Further issues to address in the FIV system are the relationship between 
determinants of virulence in vitro and pathogenesis in vivo.  This study focussed on a 
comparison of two isolates of FIV that have been used extensively as challenge 
viruses in vaccine studies.  It is not known whether viruses isolated from cats infected 
in the field are predominantly virulent and pathogenic, similar to  GL8414, or whether 
a spectrum of isolates with varying degrees of virulence and pathogenicity exist.  It is 
possible that the virulence characteristics of field isolates depend on the stage of 
infection.  Proviral loads measured in field cats by real-time PCR were comparable to 
those of cats infected with the GL8414 isolate (D.Klein, unpublished data) rather than 
the low loads detected in cats infected with the PETF14 isolate.  In future studies, it 
will be important to examine the virulence characteristics and pathogenicity of field 
isolates to establish whether particular virulence determinants exist that characterise 
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the behaviour of FIV isolates in vivo.  This will enable the selection of vaccine 
challenge strains that are most representative of field isolates and thus will impact 
upon future lentiviral vaccine strategies.  
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 FIGURE LEGENDS 
 
Figure 1. Quantification of proviral load and CD4:CD8 ratio in FIV infected cats 
during the acute phase of infection. Three cats were inoculated intraperitoneally with 
either GL8414 (Ο),  PETF14 (∇) or mock-infected with PBS ( ). (A) Proviral DNA 
load in PBMC was estimated by real-time PCR (control cats were consistently 
negative and thus are not shown). Each point represents the mean proviral load of the 
three cats in the group (+/- SE). (B) CD4:CD8 ratio was estimated by flow cytometry. 
Results represent the mean CD4:CD8 ratio of the three study groups (+/- SE). 
 
Figure 2.  Effect of FIV infection on (A) CD4+, (B) CD8+ and (C) CD8αβlow  
lymphocyte subsets.  The percentage of peripheral blood lymphoid cells expressing 
CD4 and CD8 was quantified in each of the three study groups, GL8414- infected (Ο),  
PETF14-infected ( ) or mock-infected with PBS (∇ ) by flow cytometry and the 
absolute cell number of each subset calculated from the results of haematological 
analysis.  Results are expressed as the mean (+/-SE) cell number (x109/l), * denotes 
significant difference (p=0.046).         
 
Figure 3. Quantification of proviral load in FIV infected cats during the acute and 
chronic phases of infection. Three cats were inoculated intraperitoneally with either 
GL8414 (open symbols) or PETF14 (closed symbols) and the proviral DNA load in 
PBMC was estimated by real-time PCR. The sequential proviral loads of  each cat in 
the two groups are shown as % infected PBMC.  
 
Figure 4.  Expansion of CD8αβlow+ lymphocyte subpopulations in FIV infected cats.  
Contour plots of representative analyses of one cat from each group at 144 weeks post 
infection (CON=control 612, GL8=GL8414-infected 612, PET=PETF14-infected 628). 
Boxed regions illustrate the analysis gates for each population. 
 
Figure 5. Predicted amino acid sequence of the V3 – V6 region of the FIV envelope 
glycoprotein from revertant viruses  (627W135 and 628W135) at 135 weeks post 
infection.  Lines under the sequence delineate the variable regions 3, 4, 5 and 6. 
Predicted sites for N-linked glycosylation (  ) , and residues in the V3 loop affecting 
CXCR4-usage (  ) are marked.  Sequences are shown relative to the parent molecular 
clone PETF14, and  to the GL8414  molecular clone for comparison.  Sequences were 
consistent between three independent clones. 
 
Figure 6.  Reduced fusogenicity of envelope glycoproteins from 627W135 and 628W135 
viruses.  Env genes from PETF14 (a), GL8414 (b),627W135 (c) and 628W135 (d), GL8E407K 
(e) were subcloned into the vector VR1012 and transfected into CXCR4-expressing 
AH927 cells. The empty vector VR1012 was transfected as a control (f.).  48 hours 
post-transfection the cells were fixed, stained and examined by light microscopy. 
Figures (a to f) illustrate representative syncytia observed with each construct. The 
number of syncytia per filed were enumerated, the data represent the mean number 
(n=5) of syncytia per field +/- SE. 
 
Figure 7. Impaired growth of the 627W135 and 628W135 viruses in CXCR4-expressing 
feline cells.  PETF14, GL8414,  627W135 and 628W135 viruses were used to infect AH927 
cells-expressing which had been engineered to over-express feline CXCR4.   Infection 
was performed in the presence (Ο) or absence (•) of the CXCR4-antagonist 
AMD3100.  Supernatants were collected at 9 days post infection and assayed for 
reverse transcriptase (RT) activity. Results represent the mean of duplicate samples 
and are expressed as pg/ml RT. 
 
Figure 8. Quantification of (a.) proviral load, (b.) viral load and (c.) CD8αβ low in 
FIV infected cats during the acute phase of infection. Three cats were inoculated 
intraperitoneally with either PETF14 (Ο), 627W135 (∇) or 628W135 ( ). (a.) Proviral 
DNA load in PBMC was estimated by real-time PCR.  Each point represents the mean 
% infected PBMC of the three cats in the group (+SE). (b.)  Viral load in plasma was 
estimated by real-time PCR.  Each point represents the mean number of virions per ml 
of plasma from the three cats in the group (+SE). (c.) Expansion of CD8βlow 
lymphocyte subpopulations following infection with the three isolates, expressed as 
CD8αβlow/CD8α cells.  Each point represents the mean ratio of CD8αβlow/CD8α 
cells for the three cats in each group (+SE). 
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